WO2003000718A3 - Polypeptides comprising t cell epitopes from alpha-fodrin and the uses thereof in treatment of sjögren's syndrome - Google Patents

Polypeptides comprising t cell epitopes from alpha-fodrin and the uses thereof in treatment of sjögren's syndrome Download PDF

Info

Publication number
WO2003000718A3
WO2003000718A3 PCT/JP2001/008221 JP0108221W WO03000718A3 WO 2003000718 A3 WO2003000718 A3 WO 2003000718A3 JP 0108221 W JP0108221 W JP 0108221W WO 03000718 A3 WO03000718 A3 WO 03000718A3
Authority
WO
WIPO (PCT)
Prior art keywords
fodrin
sjögren
polypeptides
syndrome
alpha
Prior art date
Application number
PCT/JP2001/008221
Other languages
French (fr)
Other versions
WO2003000718A2 (en
Inventor
Yoshio Hayashi
Original Assignee
Yoshio Hayashi
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoshio Hayashi, Fujisawa Pharmaceutical Co filed Critical Yoshio Hayashi
Priority to AU2001288087A priority Critical patent/AU2001288087A1/en
Publication of WO2003000718A2 publication Critical patent/WO2003000718A2/en
Publication of WO2003000718A3 publication Critical patent/WO2003000718A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Abstract

The present invention provides a polypeptide consisting of a partial amino acid sequence of α-fodrin containing an amino acid sequence depicted in SEQ ID No:1, SEQ ID No:2 or SEQ ID No:4, its mutant, particularly, an epitope analogue containing a sequence depicted in SEQ ID No:3, and use thereof.
PCT/JP2001/008221 2001-06-22 2001-09-21 Polypeptides comprising t cell epitopes from alpha-fodrin and the uses thereof in treatment of sjögren's syndrome WO2003000718A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001288087A AU2001288087A1 (en) 2001-06-22 2001-09-21 Polypeptides comprising t cell epitopes from alpha-fodrin and the uses thereof in treatment of sjogren's syndrome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR5897A AUPR589701A0 (en) 2001-06-22 2001-06-22 Novel peptide and use thereof
AUPR5897 2001-06-22

Publications (2)

Publication Number Publication Date
WO2003000718A2 WO2003000718A2 (en) 2003-01-03
WO2003000718A3 true WO2003000718A3 (en) 2003-08-21

Family

ID=3829866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008221 WO2003000718A2 (en) 2001-06-22 2001-09-21 Polypeptides comprising t cell epitopes from alpha-fodrin and the uses thereof in treatment of sjögren's syndrome

Country Status (2)

Country Link
AU (2) AUPR589701A0 (en)
WO (1) WO2003000718A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100572391C (en) * 2006-08-30 2009-12-23 中国科学院广州生物医药与健康研究院 Beta-fodrin antigen epitope polypeptide and screening method thereof and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2188816A1 (en) * 1996-04-23 1997-10-24 Takeda Chemical Industries, Ltd. Composition containing .alpha.-fodrin or .alpha.- fodrin fragment protein
JPH10251157A (en) * 1996-04-23 1998-09-22 Yoshio Hayashi Medicine containing alpha-fodrin or alpha-fodrin fragment protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2188816A1 (en) * 1996-04-23 1997-10-24 Takeda Chemical Industries, Ltd. Composition containing .alpha.-fodrin or .alpha.- fodrin fragment protein
JPH10251157A (en) * 1996-04-23 1998-09-22 Yoshio Hayashi Medicine containing alpha-fodrin or alpha-fodrin fragment protein

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199820, Derwent World Patents Index; Class B04, AN 1998-217935, XP002223821 *
HANEJI N ET AL: "Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome.", SCIENCE. UNITED STATES 25 APR 1997, vol. 276, no. 5312, 25 April 1997 (1997-04-25), pages 604 - 607, XP002223818, ISSN: 0036-8075 *
ISHIMARU N ET AL: "Severe destructive autoimmune lesions with aging in murine Sjögren's syndrome through Fas-mediated apoptosis.", AMERICAN JOURNAL OF PATHOLOGY. UNITED STATES MAY 2000, vol. 156, no. 5, May 2000 (2000-05-01), pages 1557 - 1564, XP002223819, ISSN: 0002-9440 *
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 14 31 December 1998 (1998-12-31) *
SAEGUSA K ET AL: "Mechanisms of neonatal tolerance induced in an animal model for primary Sjögren's syndrome by intravenous administration of autoantigen.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY. ENGLAND SEP 2000, vol. 52, no. 3, September 2000 (2000-09-01), pages 264 - 270, XP002223820, ISSN: 0300-9475 *

Also Published As

Publication number Publication date
AU2001288087A1 (en) 2003-01-08
AUPR589701A0 (en) 2001-07-19
WO2003000718A2 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
ZA9810679B (en) Antimicrobial peptides.
AU2001290837A1 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
WO2004043382A3 (en) Enhanced variants of erythropoietin and methods of use
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
EP2360259A3 (en) Promyostatin peptides and methods of using same
MXPA04000597A (en) Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine.
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
MX9503362A (en) Novel mutant br96 antibodies and functional equivalents reactive with human carcinomas.
WO1999003987A3 (en) Syncytial respiratory virus epitopes and antibodies comprising them, useful in diagnosis and therapy
WO2003031598A3 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
WO2002008426A3 (en) Fh-binding protein of streptococcus pneumoniae
WO2006090090A3 (en) Hiv epitopes and pharmaceutical composition containing same
AU2001248822A1 (en) Gd3-mimetic peptides
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
WO2000058465A3 (en) Flint polypeptide analogs
WO1996002572A3 (en) Antigenic polypeptide sequence of factor viii, fragments and/or epitopes thereof
WO2003000718A3 (en) Polypeptides comprising t cell epitopes from alpha-fodrin and the uses thereof in treatment of sjögren's syndrome
EP1251176A3 (en) Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
WO2003095493A3 (en) Toxin-related antibodies with antimicrobial and antiviral activity
WO2001011937A3 (en) Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines
WO1997039029A3 (en) An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
AU2003264535A1 (en) Tumor antigen protein and utilization thereof
WO2002030975A3 (en) Antifungal peptides
WO2001098355A3 (en) Cgi-69 compositions and methods of use
PT1847607E (en) Antibodies against the p51 protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP